BRIEF-Pfizer Says Vesper-1 Shows Nearly 16% Weight Loss At 32 Weeks On 2.4 Mg Weekly Berobenatide

Pfizer Inc.

Pfizer Inc.

PFE

0.00

June 6 (Reuters) - Pfizer Inc PFE.N:

  • ROBUST PHASE 2B EFFICACY AND FAVORABLE TOLERABILITY SUPPORT MONTHLY DOSING FOR PFIZER’S GLP-1 RA BEROBENATIDE

  • PFIZER - VESPER-1 SHOWS NEARLY 16% WEIGHT LOSS AT 32 WEEKS ON 2.4 MG WEEKLY BEROBENATIDE

  • PFIZER - PLANS 10 PHASE 3 BEROBENATIDE STUDIES IN 2026 AS PART OF 20+ OBESITY TRIALS

Source text: ID:nBw37zF6pa

Further company coverage: PFE.N


This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.